A Phase 3 interventional study of Rifamycin SV-MMX® and Ciprofloxacin in Traveler's Diarrhea, sponsored by Dr. Falk Pharma GmbH. Completed at 19 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-02-27.
Sponsored by Dr. Falk Pharma GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Diarrhea with a site in India — none open to participants now, 1 under way, none of them phase 3. Diarrhea · India.
Among the 42 studies in Diarrhea with a site in India, this one is the 21st largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2010, is one of 9 in phase 3, and was the 22nd registered.
880 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
Browse Diarrhea studies →None of the 42 studies in Diarrhea with a site in India is open now. The open studies under Diarrhea, anywhere →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 11 · Phase 4 3
First in 1998; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 835 is above the median of 137 across 740 interventional studies indexed under Diarrhea.
Median enrollment 918 across the 40 interventional studies, 12,898 across the 2 observational. Of the 38 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 42 have an industry lead sponsor. The 10 most frequent:
Dr. Falk Pharma GmbH is the lead sponsor of 39 studies on the registry; 3 are open to participants now.
Dr. Falk Pharma GmbH has 1 study filed under Diarrhea — fewer than ten, so there is no comparison to draw.
1 of the studies in Diarrhea with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06168097Asian Institute of Gastroenterology, IndiaThe Use of MicroRNAs Dysregulation as Potential Biomarkers for Effective Diagnosis of Endometriosis | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Diarrhea with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rifamycin SV-MMX® 200 mg tablets
Drug: Rifamycin SV-MMX®
Ciprofloxacin 500 mg capsules
Drug: Ciprofloxacin
2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
Time to Last Unformed Stool (TLUS)
Time to Last Unformed Stool (TLUS), defined as the interval in hours between the first dose of study drug and the last unformed stool passed, after which clinical cure was declared.
Time frame: 5 days
Number of Patients With Clinical Cure
Clinical Cure Rate: 24-hour period with no clinical symptoms except mild flatulence, no fever, no watery stools and no more than 2 soft stools OR 48-hour period with no stools or only formed stools, and no fever, with our without symptoms of enteric infection.
Time frame: 5 days
Recruited from November 2010 until January 2016
| Milestone | Rifamycin Group | Ciprofloxacin Group |
|---|---|---|
| Started | 420 | 415 |
| Completed | 409 | 405 |
| Not completed | 11 | 10 |
Time to Last Unformed Stool (TLUS), defined as the interval in hours between the first dose of study drug and the last unformed stool passed, after which clinical cure was declared.
| hours | Group A | Group B |
|---|---|---|
| Time to Last Unformed Stool (TLUS) | 44.3 (40.1 to 47.5) | 40.3 (33.5 to 44.8) |
Clinical Cure Rate: 24-hour period with no clinical symptoms except mild flatulence, no fever, no watery stools and no more than 2 soft stools OR 48-hour period with no stools or only formed stools, and no fever, with our without symptoms of enteric infection.
| Participants | Group A | Group B |
|---|---|---|
| Number of Patients With Clinical Cure | 357 | 352 |
Collected over An average of 1 month. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A | 0/420 (0%) | 0/420 (0%) | 36/420 (8.6%) |
| Group B | 0/415 (0%) | 0/415 (0%) | 32/415 (7.7%) |
| Event | Group A | Group B |
|---|---|---|
| HeadacheNervous system disorders | 13/420 | 9/415 |
| DiarrhoeaGastrointestinal disorders | 8/420 | 6/415 |
| NauseaGastrointestinal disorders | 6/420 | 6/415 |
| FlatulenceGastrointestinal disorders | 5/420 | 6/415 |
| Abdominal painGastrointestinal disorders | 4/420 | 5/415 |
Baseline results were reported for Full Analysis Set, which included all randomised patients (as randomised) who received at least one dose of study medication. Patients with uncertainty as to whether they had received study medication or not (e.g., due to lost to follow-up) were included.
| Age, Continuous(years) | Group A | Group B | Total |
|---|---|---|---|
| Mean | 40.0 ± 16.1 | 40.4 ± 16.6 | 40.2 ± 16.3 |
| Sex: Female, Male(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Female | 215 | 197 | 412 |
| Male | 205 | 218 | 423 |
| Race (NIH/OMB)(Participants) | Group A | Group B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 75 | 68 | 143 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 342 | 344 | 686 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(participants) | Group A | Group B | Total |
|---|---|---|---|
| Ecuador | 1 | 0 | 1 |
| Guatemala | 14 | 15 | 29 |
| India | 405 | 400 | 805 |
The record gives a start of Nov 2010, a primary completion of Jan 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2019, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.